ASRS
ACAD icon

Arizona State Retirement System’s Acadia Pharmaceuticals ACAD Stock Holding History

Arizona State Retirement System’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Sell
31,755
-774
-2% -$17K ﹤0.01% 1294
2026
Q1 		$724K Sell
32,529
-518
-2% -$12.4K ﹤0.01% 1280
2025
Q4 		$883K Sell
33,047
-1,606
-5% -$38.4K ﹤0.01% 1176
2025
Q3 		$739K Buy
34,653
+3,014
+10% +$71.3K ﹤0.01% 1296
2025
Q2 		$682K Buy
31,639
+631
+2% +$11.7K ﹤0.01% 1300
2025
Q1 		$515K Sell
31,008
-265
-0.8% -$4.81K ﹤0.01% 1403
2024
Q4 		$574K Buy
31,273
+433
+1% +$6.99K ﹤0.01% 1420
2024
Q3 		$474K Buy
30,840
+857
+3% +$14.3K ﹤0.01% 1513
2024
Q2 		$487K Buy
29,983
+655
+2% +$10.6K ﹤0.01% 1450
2024
Q1 		$542K Sell
29,328
-423
-1% -$10.5K ﹤0.01% 1396
2023
Q4 		$932K Sell
29,751
-348
-1% -$8.31K 0.01% 1079
2023
Q3 		$627K Sell
30,099
-1,798
-6% -$48.8K 0.01% 1251
2023
Q2 		$764K Sell
31,897
-3,293
-9% -$73.2K 0.01% 1172
2023
Q1 		$662K Buy
35,190
+939
+3% +$17.9K 0.01% 1249
2022
Q4 		$545K Buy
34,251
+1,350
+4% +$21.1K 0.01% 1320
2022
Q3 		$538K Buy
32,901
+227
+0.7% +$3.68K 0.01% 1285
2022
Q2 		$460K Buy
32,674
+83
+0.3% +$1.55K ﹤0.01% 1407
2022
Q1 		$789K Buy
32,591
+164
+0.5% +$3.97K 0.01% 1194
2021
Q4 		$757K Sell
32,427
-297
-0.9% -$5.97K 0.01% 1281
2021
Q3 		$544K Buy
32,724
+95
+0.3% +$1.83K ﹤0.01% 1494
2021
Q2 		$796K Sell
32,629
-2,080
-6% -$46.9K 0.01% 1262
2021
Q1 		$895K Buy
34,709
+158
+0.5% +$6.96K 0.01% 1199
2020
Q4 		$1.85M Sell
34,551
-719
-2% -$35.7K 0.02% 723
2020
Q3 		$1.46M Buy
35,270
+8,974
+34% +$388K 0.01% 743
2020
Q2 		$1.27M Sell
26,296
-824
-3% -$39.6K 0.02% 654
2020
Q1 		$1.15M Buy
+27,120
New +$1.12M 0.02% 623

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arizona State Retirement System's ACAD Position: Q2 2026 in Review

Arizona State Retirement System reduced its Acadia Pharmaceuticals (ACAD) stake by 2.4% in Q2 2026, selling an estimated $17K and leaving 31,755 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

Arizona State Retirement System first reported a position in ACAD in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.85M in Q4 2020. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Arizona State Retirement System held 31,755 shares of Acadia Pharmaceuticals worth $803K as of Q2 2026.
  • Arizona State Retirement System sold 774 Acadia Pharmaceuticals shares in Q2 2026, an estimated $17K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Arizona State Retirement System's portfolio in Q2 2026, its #1294 holding.
  • Arizona State Retirement System first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Arizona State Retirement System's Acadia Pharmaceuticals position peaked at $1.85M in Q4 2020.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Arizona State Retirement System's 13F filing for Q2 2026, filed 7 Aug 2026.